Literature DB >> 11882011

Tumour suppressor genes in sporadic epithelial ovarian cancer.

Ying Liu1, Trivadi S Ganesan.   

Abstract

Ovarian cancer is the most frequent cause of death from gynaecological malignancies in the western world, and sporadic epithelial ovarian cancer is its most predominant form. The aetiology of sporadic ovarian cancer remains unknown. Genetic studies have enabled a better understanding of the evolution of tumour progression. A major focus of research has been to identify tumour suppressor genes implicated in sporadic ovarian cancer over the past decade. Several tumour suppressor genes have been identified by strategies such as positional cloning and differential expression display. Further research is warranted to understand fully their contribution to the pathogenesis of sporadic ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11882011     DOI: 10.1530/rep.0.1230341

Source DB:  PubMed          Journal:  Reproduction        ISSN: 1470-1626            Impact factor:   3.906


  9 in total

1.  E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer.

Authors:  Narasimhan Kothandaraman; Vladimir B Bajic; Pang N K Brendan; Chan Y Huak; Peh B Keow; Khalil Razvi; Manuel Salto-Tellez; Mahesh Choolani
Journal:  BMC Cancer       Date:  2010-02-24       Impact factor: 4.430

Review 2.  Large-scale genomic analysis of ovarian carcinomas.

Authors:  Kylie L Gorringe; Ian G Campbell
Journal:  Mol Oncol       Date:  2008-12-24       Impact factor: 6.603

Review 3.  Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.

Authors:  Sabita N Saldanha; Trygve O Tollefsbol
Journal:  J Cell Physiol       Date:  2014-04       Impact factor: 6.384

Review 4.  Alterations of common chromosome fragile sites in hematopoietic malignancies.

Authors:  Hideshi Ishii; Yusuke Furukawa
Journal:  Int J Hematol       Date:  2004-04       Impact factor: 2.490

5.  The human homologue of unc-93 maps to chromosome 6q27 - characterisation and analysis in sporadic epithelial ovarian cancer.

Authors:  Ying Liu; Phillippa Dodds; Gracy Emilion; Andrew J Mungall; Ian Dunham; Stephan Beck; R Spencer Wells; F Mark L Charnock; Trivadi S Ganesan
Journal:  BMC Genet       Date:  2002-10-15       Impact factor: 2.797

6.  Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy.

Authors:  A D Santin; F Zhan; S Cane'; S Bellone; M Palmieri; M Thomas; A Burnett; J J Roman; M J Cannon; J Shaughnessy; S Pecorelli
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

7.  Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma.

Authors:  J M Arnold; P R Huggard; M Cummings; G A Ramm; G Chenevix-Trench
Journal:  Br J Cancer       Date:  2005-06-06       Impact factor: 7.640

8.  Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer.

Authors:  J Lai; J Flanagan; W A Phillips; G Chenevix-Trench; J Arnold
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

9.  Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity.

Authors:  P Wojnarowicz; K Gambaro; M de Ladurantaye; M C J Quinn; D Provencher; A-M Mes-Masson; P N Tonin
Journal:  Oncogenesis       Date:  2012-09-10       Impact factor: 7.485

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.